{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:17:32Z","timestamp":1793945852290,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Novartis Pharmaceuticals Australia Pty Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12886-016-0207-3","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T21:54:35Z","timestamp":1458770075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study"],"prefix":"10.1186","volume":"16","author":[{"given":"Jennifer J.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Markey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol P.","family":"Kurstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn H.","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"207_CR1","doi-asserted-by":"crossref","unstructured":"Deloitte Access Economics. Eyes on the future: A clear outlook on age-related macular degeneration. Macular Degeneration Foundation. 2011. Available at www.mdfoundation.com.au\/LatestNews\/MDFoundationDeloitteAccessEconomicsReport2011.pdf . Accessed 15 March 2016.","DOI":"10.1201\/b14548-5"},{"key":"207_CR2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"207_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57\u201365.","journal-title":"Ophthalmology"},{"key":"207_CR4","volume-title":"Lucentis Australian Prescribing Information","author":"Novartis Pharmaceuticals Australia","year":"2011","unstructured":"Novartis Pharmaceuticals Australia. Lucentis Australian Prescribing Information. 2011."},{"key":"207_CR5","unstructured":"Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R, on behalf of the EXCITE study group. Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial. Invest Ophthalmol Vis Sci. 2009;50:2374."},{"key":"207_CR6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40266-013-0077-9","volume":"30","author":"JE Frampton","year":"2013","unstructured":"Frampton JE. Ranibizumab: A review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging. 2013;30:331\u201358.","journal-title":"Drugs Aging"},{"key":"207_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1167\/iovs.09-3813","volume":"51","author":"FG Holz","year":"2010","unstructured":"Holz FG, Korobelnik JF, Laznetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, et al. The effects of a flexible visual acuity-driven regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci. 2010;51:405\u201312.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"207_CR8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118:663\u201371.","journal-title":"Ophthalmology"},{"key":"207_CR9","first-page":"786870","volume":"2012","author":"JL Kovach","year":"2012","unstructured":"Kovach JL, Schwartz SG, Flynn Jr HW, Scott IU. Anti-VEGF treatment strategies for wet AMD. J Ophthamol. 2012;2012:786870.","journal-title":"J Ophthamol"},{"key":"207_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43\u201358.","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"207_CR11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"key":"207_CR12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE. Ranibizumab and bevacizumab for treatment of neovascular age-related Macular degeneration. Two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"207_CR13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, et al. the HARBOR study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356.","journal-title":"Ophthalmology"},{"key":"207_CR14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","volume":"117","author":"OP Gupta","year":"2010","unstructured":"Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2010;117:2134\u201340.","journal-title":"Ophthalmology"},{"key":"207_CR15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IAE.0b013e3181de5609","volume":"31","author":"H Oubraham","year":"2011","unstructured":"Oubraham H, Cohen SY, Samimi S, Marotte D, Bouzaher I, Bonicel P, et al. Inject and extend dosing versus dosing as needed. A comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina. 2011;31:26\u201330.","journal-title":"Retina"},{"key":"207_CR16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/IAE.0b013e3182831265","volume":"33","author":"N Toalster","year":"2013","unstructured":"Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina. 2013;33:1351\u20138.","journal-title":"Retina"},{"key":"207_CR17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/IAE.0000000000000134","volume":"34","author":"F Abedi","year":"2014","unstructured":"Abedi F, Wickremasinghe S, Islam AFM, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration. A treat-and-extend protocol over 2\u00a0years. Retina. 2014;34:1531\u20138.","journal-title":"Retina"},{"key":"207_CR18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/eye.2014.321","volume":"29","author":"C Gianniou","year":"2015","unstructured":"Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye. 2015;29:450\u20131.","journal-title":"Eye"},{"key":"207_CR19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ophtha.2013.09.050","volume":"121","author":"MC Gillies","year":"2014","unstructured":"Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, Hunyor AP, et al. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology. 2014;121:676\u201381.","journal-title":"Ophthalmology"},{"key":"207_CR20","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","volume":"122","author":"JJ Arnold","year":"2015","unstructured":"Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, et al. Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122:1212\u20131219.","journal-title":"Ophthalmology."},{"key":"207_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679\u201380.","journal-title":"Am J Ophthalmol"},{"key":"207_CR22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser P, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"207_CR23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald JE, Daniel E, Huang J, Ying GS, Maquire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatment trials. Ophthalmology. 2014;121:150\u201361.","journal-title":"Ophthalmology"},{"key":"207_CR24","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ophtha.2007.09.008","volume":"114","author":"MA Brantley Jr","year":"2007","unstructured":"Brantley Jr MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;114:2168\u201373.","journal-title":"Ophthalmology"},{"key":"207_CR25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ophtha.2013.01.014","volume":"120","author":"F Abedi","year":"2013","unstructured":"Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PM. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology. 2013;120:1641\u20138.","journal-title":"Ophthalmology"},{"key":"207_CR26","unstructured":"National Institute of Health Clinical Trials Registration Number. http:\/\/clinicaltrials.gov\/show\/NCT01972789 Accessed 15 March 2016."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-016-0207-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T22:45:57Z","timestamp":1655333157000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-016-0207-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["207"],"URL":"https:\/\/doi.org\/10.1186\/s12886-016-0207-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]},"article-number":"31"}}